While combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists holds promise for addressing residual cardiovascular risk in type 2 diabetes, its optimal use requires nuanced consideration of patient subpopulations, safety, and cost-effectiveness. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.